Schedule of Stock-Based Compensation Expense Classified in Research and Development Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Stock-based compensation expense	$ 15,009	$ 2,044
Sales And Marketing Expenses [Member]
Stock-based compensation expense	1,177	278
General and Administrative Expense [Member]
Stock-based compensation expense	12,799	1,304
Research and Development Expense [Member]
Stock-based compensation expense	1,033	462
Research and Development Expense [Member] | Lucid Diagnostics Inc [Member]
Stock-based compensation expense	9,599	65
Lucid Diagnostics Inc 2018 Equity Plan [Member] | Sales And Marketing Expenses [Member]
Stock-based compensation expense	8
Lucid Diagnostics Inc 2018 Equity Plan [Member] | General and Administrative Expense [Member]
Stock-based compensation expense	9,073
Lucid Diagnostics Inc 2018 Equity Plan [Member] | Research and Development Expense [Member]
Stock-based compensation expense	66	52
PAVmed Inc 2014 Equity Plan [Member] | Sales And Marketing Expenses [Member]
Stock-based compensation expense	202
PAVmed Inc 2014 Equity Plan [Member] | General and Administrative Expense [Member]
Stock-based compensation expense	38
PAVmed Inc 2014 Equity Plan [Member] | Research and Development Expense [Member]
Stock-based compensation expense	$ 212	$ 13